Biomarkers in Tumor Tissue Samples From Younger Patients With Rhabdomyosarcoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2015 by Children's Oncology Group
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Children's Oncology Group
ClinicalTrials.gov Identifier:
NCT01496573
First received: December 16, 2011
Last updated: May 7, 2015
Last verified: May 2015

December 16, 2011
May 7, 2015
December 2011
January 2100   (final data collection date for primary outcome measure)
CRKL expression at the protein level [ Time Frame: 1 month ] [ Designated as safety issue: No ]
CRKL expression at the protein level [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01496573 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Biomarkers in Tumor Tissue Samples From Younger Patients With Rhabdomyosarcoma
Observational - CRKL Expression at the Protein Level in Rhabdomyosarcoma Tumors by Tissue Microarray (TMA)

This research trial studies biomarkers in tumor tissue samples from younger patients with rhabdomyosarcoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer

PRIMARY OBJECTIVES:

I. To demonstrate CRKL expression at the protein level in rhabdomyosarcoma tumors by tissue microarray (TMA).

OUTLINE:

Archived tumor tissue samples are analyzed for CRKL expression.

Observational
Observational Model: Case-Only
Time Perspective: Retrospective
Not Provided
Retention:   Samples With DNA
Description:

tumor tissue

Non-Probability Sample

Alveolar rhabdomyosarcoma and embryonal rhabdomyosarcoma

  • Alveolar Childhood Rhabdomyosarcoma
  • Childhood Rhabdomyosarcoma
  • Embryonal Childhood Rhabdomyosarcoma
Other: laboratory biomarker analysis
Correlative studies
Basic science (biomarker analysis)
Archived tumor tissue samples are analyzed for CRKL expression.
Intervention: Other: laboratory biomarker analysis
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
77
Not Provided
January 2100   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Alveolar rhabdomyosarcoma and embryonal rhabdomyosarcoma specimens from the Children Oncology Group (COG) tumor microarrays (TMAs)
Both
Not Provided
No
United States
 
NCT01496573
ARST12B4, NCI-2012-00094
No
Children's Oncology Group
Children's Oncology Group
National Cancer Institute (NCI)
Principal Investigator: Lee Helman, MD Children's Oncology Group
Children's Oncology Group
May 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP